Drug Profile
INO 5401
Alternative Names: INO-5401Latest Information Update: 08 Mar 2023
Price :
$50
*
At a glance
- Originator Inovio Pharmaceuticals
- Developer Inovio Pharmaceuticals; Regeneron Pharmaceuticals
- Class Antineoplastics; DNA; Immunotherapies
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Glioblastoma
- Phase I Cancer
- Discontinued Urogenital cancer
Most Recent Events
- 08 Mar 2023 Inovio Pharmaceuticals completes a phase I/II trial for Glioblastoma (Combination therapy, Newly diagnosed) in USA (IM), prior to March 2023 (NCT03491683)
- 27 May 2022 Efficacy data from a phase I/II trial in Glioblastoma released by Inovio Pharmaceuticals
- 30 Nov 2021 Interim efficacy and adverse events data from a phase I/II trial in glioblastoma released by Inovio Pharmaceuticals